Clopidogrel

• UNSPSC Description:

  Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

• Target Antigen:

  P2Y Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/clopidogrel.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)|Methanol : ≥ 100 mg/mL

• Smiles:

  ClC1=C(C=CC=C1)[C@H](N2CCC3=C(C2)C=CS3)C(OC)=O

• Molecular Weight:

  321.82

• References & Citations:

  [1]Zongyu Zheng, et al. Clopidogrel Reduces Fibronectin Accumulation and Improves Diabetes-Induced Renal Fibrosis. Int J Biol Sci. 2019 Jan.|[2]An insight into the interaction between clopidogrel and proton pump inhibitors By Shah, Bhavik S.; Parmar, Sanjay A.; Mahajan, Shailaja; Mehta, Anita A. From Current Drug Metabolism (2012), 13(2),225-235.ACS Nano. 2023 Mar 27.|Drug Des Devel Ther. 2020 Dec 21;14:5599-5610.|Front Pharmacol. 2022 Jan 10;12:792263.|Front Pharmacol. 2024 Oct 23:15:1496639.|Int J Biol Sci. 2019 Jan 1;15(1):239-252.|Int J Mol Sci. 2022, 23(16), 9118.|iScience. 2024 Feb 5;27(3):109134.|J Adv Res. 2024 Jul 5:S2090-1232(24)00269-8.|J Appl Physiol (1985). 2021 Sep 30.|J Pharm Health Care Sci. 2021 May 4;7(1):18.|Open Chem. 2020 Jun.|Research Square Preprint. 2023 Nov 14.|Theranostics. 2023; 13(6):2040-2056.|Thromb J. 2024 Jul 10;22(1):59.|Thromb Res. 2023 May 8.|Thromb Res. 2024 Apr 16.|ACS Omega. 2020 Aug 4;5(32):19995-20003.|Am J Transl Res. 2020 May 15;12(5):1741-1753.|Foods. 2023 Feb 10;12(4):777.|Front Pharmacol. 2021 Oct 8:12:734603.|J Ethnopharmacol. 2024 Aug 22:118707.|J Food Biochem. 2020 Sep;44(9):e13352.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Launched

• CAS Number:

  113665-84-2